Immune Checkpoint Inhibitor - Associated Renal Tubular Acidosis and Nephrogenic Diabetes Insipidus: A Case Report.

ABSTRACT:

Introduction

Immunotherapy has significantly changed the landscape of cancer treatment, yet it can lead to immune-related adverse events, including renal complications. This report highlights a unique case of tubular injury associated with pembrolizumab in a patient with malignant melanoma.

Case presentation

A 42-year-old female patient with malignant melanoma received adjuvant pembrolizumab treatment. Three months later, she presented with profound weakness, myalgia, abdominal pain, polyuria, and thirst. Laboratory tests revealed acute kidney injury, significant proteinuria, renal tubular acidosis (RTA) with severe electrolyte imbalances, and nephrogenic diabetes insipidus (NDI). Management involved withholding pembrolizumab, initiating high-dose prednisone therapy, and cor

SUBMITTER: Cohen I 

PROVIDER: S-EPMC12503474 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature